New England Journal of Medicine· 2014Q1· Clinical trial
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- 1,242citations
- Q1SCImago
- 2014year
Short summary
Romosozumab, a monoclonal antibody targeting sclerostin, significantly increased bone mineral density in postmenopausal women with low bone mass, with the 210-mg monthly dose yielding an 11.3% increase at the lumbar spine after 12 months.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Orthopedics and Sports Medicine
Orthopedics and Sports MedicineMedicine